KIADIS news, videos and press releases
For more news please use our advanced search feature.
KIADIS - More news...
KIADIS - More news...
- Notice of Annual General Meeting of Shareholders
- Final results of the Offer for Kiadis: 97.39% of Kiadis Shares in total committed under the Offer
- Delisting of Kiadis will be effective on 25 May 2021
- Sanofi completes Kiadis acquisition
- Sanofi declares the Offer for Kiadis unconditional
- Kiadis employee options committed under the Sanofi Offer
- Kiadis Pharma announces annual results for the year ended December 31, 2020
- Kiadis EGM adopts all resolutions related to the recommended public offer by Sanofi
- Kiadis issues shares to Kreos Capital following agreed conversion of convertible bonds
- Sanofi launches recommended cash offer for all shares in Kiadis
- Kiadis Shareholders give irrevocable commitment to tender 36.6% of the shares under the offer by Sanofi
- Kiadis announces multiple abstracts related to its K-NK-cell therapy platform have been accepted for presentation at TCT, the Combined Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR
- Kiadis draws €20 million from bridge loan with Sanofi
- Sanofi and Kiadis satisfy competition condition related to the tender offer
- Kiadis issues “holdback” shares to former Cytosen shareholders
- Kiadis announces new data at the 2020 ASH Annual Meeting and Exposition
- Update on the intended offer by Sanofi for Kiadis
- Kiadis to present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
- Kiadis issues options to newly hired employees to meet its existing obligations
- Kiadis announces presentations at the 2020 ASH Annual Meeting and Exposition
- Kiadis announces new data related to its K-NK cell therapy platform presented today at the SITC Annual Meeting
- Sanofi offers to acquire Kiadis for €308 million
- Kiadis announces presentation at the 2020 Society for Immunotherapy of Cancer Annual Meeting
- Kiadis announces the placement of €5 million convertible bonds with Kreos
- Kiadis announces results for the six months ended June 30, 2020 and significant progress made to date in 2020 in all development programs
- Kiadis and Gulf Coast Regional Blood Center announce collaboration to provide universal donor material for K-NK cell therapy programs
- Kiadis receives $9.5 million from the Advanced Regenerative Manufacturing Institute’s BioFabUSA Program to fund Kiadis K-NK cell COVID-19 therapy
- Kiadis announces U.S. FDA approval of the Abigail Wexner Research Institute at Nationwide Children’s Hospital’s IND for a COVID-19 clinical trial with off-the-shelf K-NK cells using Kiadis’ proprietary platforms
- Kiadis announces investor events for September 2020
- Kiadis announces new data demonstrating FC21-NK cells were well tolerated and showed encouraging signs of antitumor and suspected antimicrobial activity in 13 patients with relapsed/refractory acute myeloid leukemia (R/R AML)
